BBIO - BridgeBio Pharma, Inc. News

Trump Administration Reaches New Drug Pricing Agreement With Nine Pharma Firms

https://www.whitehouse.gov/fact-sheets/2026/08/fact-sheet-president-donald-j-trump-announces-deal-wi

BridgeBio Announces Agreement with U.S. Government to Improve Affordability and Access to Critical M

- This voluntary agreement expands access for Medicaid patients to BridgeBio's currently marketed me

Reported Earlier, BridgeBio Reports New Data Suggesting Attruby Could Help Reverse Some Heart Damage

BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-st

Acoramidis Demonstrates Reversal of Cardiac Structural Disease Progression and Functional Decline an

- Acoramidis is the first therapy shown to potentially reverse cardiac structural disease progressio

BridgeBio Pharma Doses First Patient In ASCEND-ATTR Trial To Evaluate Effects Of Acoramidis To Enhan

BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-st

BridgeBio Announces First Participant Dosed in ASCEND-ATTR, a Phase 3b/4 Study Evaluating the Long-T

- The ASCEND-ATTR study builds on the Phase 3 ATTRibute-CM CMR substudy results previously shared he

BridgeBio Q2 Sales Jump 120% as Attruby Drives Commercial Momentum

BBIO's Q2 sales jump 120% as Attruby drives growth, while higher spending widens the loss and raises

Why BBIO Rose 24% in Three Months and Whether the Rally Can Continue

BridgeBio's 24% three-month rally faces a higher bar as Attruby growth and pipeline catalysts compet

Is BBIO a Buy as Fast Sales Growth Meets a Steep Valuation Premium?

BridgeBio's fast-growing Attruby sales and pipeline expansion face a steep valuation premium, contin

BridgeBio Pharma To Present Two Oral Presentations, Three Posters On New Acoramidis Data In Individu

BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a biopharmaceut

BridgeBio to Present New Acoramidis Data from Open-Label Extension Analyses in ATTR-CM at ESC Congre

PALO ALTO, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeB

10 Health Care Stocks Whale Activity In Today’s Session

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

fool.com

BridgeBio Stock Has Soared 29% in Just 3 Months. Here's Why Wall Street Thinks It Could Go Even High

Sales of BridgeBio's cutting-edge heart drug nearly tripled year over year in the second quarter. Th

BridgeBio Pharma Announces Pricing of Oversubscribed Secondary Offering that Diversifies its Institu

- The transaction supports the evolution of the Company's shareholder base toward further high-quali

BridgeBio Pharma Launches Secondary Public Offering Of 5M Shares Of Common Stock By Selling Stockhol

BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio"), a commercial-stage, multi-product biopha

BridgeBio Pharma Announces Launch of Secondary Offering of Common Stock on Behalf of an Existing Sha

PALO ALTO, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeB

Truist Securities Maintains Buy on BridgeBio Pharma, Raises Price Target to $107

Truist Securities analyst Danielle Brill maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and

Canaccord Genuity Maintains Buy on BridgeBio Pharma, Raises Price Target to $106

Canaccord Genuity analyst Whitney Ijem maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and ra

JP Morgan Maintains Overweight on BridgeBio Pharma, Raises Price Target to $111

JP Morgan analyst Anupam Rama maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and rais

defenseworld.net

BridgeBio Pharma Q2 Earnings Call Highlights

BridgeBio Pharma (NASDAQ: BBIO) reported continued growth for its ATTR cardiomyopathy treatment Attr

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeB

BridgeBio Q2 Earnings Miss, Revenues Beat as Attruby Sales Surge

BBIO's Q2 loss misses estimates, but revenues beat expectations as Attruby sales more than tripled,

seekingalpha.com

BridgeBio: Attruby Delivers In Q2, Expect Three New Launches In 12 Months

BridgeBio (BBIO) delivered a Q2 beat, reaffirmed $1B+ 2026 Attruby/Beyonttra global sales guidance,

B of A Securities Maintains Buy on BridgeBio Pharma, Raises Price Target to $104

B of A Securities analyst Geoff Meacham maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and r

TD Cowen Maintains Buy on BridgeBio Pharma, Raises Price Target to $110

TD Cowen analyst Tyler Van Buren maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises t

Morgan Stanley Maintains Overweight on BridgeBio Pharma, Lowers Price Target to $97

Morgan Stanley analyst Sean Laaman maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and

4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year

Vertex Pharmaceuticals, Amylyx Pharmaceuticals, Praxis Precision Medicines and BridgeBio Pharma face

Piper Sandler Maintains Overweight on BridgeBio Pharma, Raises Price Target to $115

Piper Sandler analyst Biren Amin maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and r

Wells Fargo Maintains Overweight on BridgeBio Pharma, Raises Price Target to $102

Wells Fargo analyst Derek Archila maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and

seekingalpha.com

BridgeBio Pharma, Inc. (BBIO) Q2 2026 Earnings Call Transcript

BridgeBio Pharma (BBIO) Reports Q2 Loss, Tops Revenue Estimates

BridgeBio Pharma (BBIO) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus

marketbeat.com

BridgeBio Pharma Q2 Earnings Call Highlights

BridgeBio Pharma NASDAQ: BBIO reported continued growth for its ATTR cardiomyopathy treatment Attrub

BridgeBio Pharma Q2 EPS $(0.78) Misses $(0.59) Estimate, Sales $243.676M Beat $218.743M Estimate

BridgeBio Pharma (NASDAQ:BBIO) reported quarterly losses of $(0.78) per share which missed the analy

Earnings Volatility Watch: Applied Materials and 10 Other Stocks Could See Double-Digit Moves This W

Applied Materials, Coherent, CoreWeave and eight other names carry double-digit implied earnings mov

defenseworld.net

California State Teachers Retirement System Boosts Stock Position in BridgeBio Pharma, Inc. $BBIO

California State Teachers Retirement System boosted its stake in shares of BridgeBio Pharma, Inc. (N

BridgeBio to Report Second Quarter 2026 Financial Results and Commercial Updates on August 10, 2026

PALO ALTO, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeB

fool.com

1 Top Wall Street Analyst Thinks This Stock Could Soar 95% Over the Next 12 Months. Here's Why I Agr

Additional FDA decisions could unlock new growth opportunities. Revenue is expected to nearly double

BridgeBio Pharma Announces FDA Accepts For Filing Its New Drug Application For Encaleret To Treat Au

BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-st

Citigroup Maintains Neutral on BridgeBio Pharma, Raises Price Target to $93

Citigroup analyst Eric Joseph maintains BridgeBio Pharma (NASDAQ:BBIO) with a Neutral and raises

Keysight To Rally Over 24%? Here Are 10 Top Analyst Forecasts For Monday

Wall Street analysts change outlook on top names. Complete view of analyst rating changes including

HC Wainwright & Co. Maintains Buy on BridgeBio Pharma, Raises Price Target to $120

HC Wainwright & Co. analyst Raghuram Selvaraju maintains BridgeBio Pharma (NASDAQ:BBIO) with

Ionis, AstraZeneca Stumble in ATTR-CM Trial as Rivals Stand to Gain

Ionis and AstraZeneca's Phase 3 ATTR-CM trial misses its primary goal, analyst says the outcome

Aehr Test Systems, Lam Research, Applied Materials And Other Big Stocks Moving Higher On Thursday

U.S. stocks higher, Nasdaq up 150+ points. Aehr Test Systems shares rose 13.6%. Other big gainers in

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Gainers Virax Biolabs Group (NASDAQ:VRAX) stock increased by 134.0% to $7.44 during Thursday's

Why Ultra Clean Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket

Stocks moving: RPGL +54.5%, EDBL +42.5%, SDOT +27.4%, BJDX +24.6%, AP +19.9%, SUNE +18%, ALNY +15.3%

BridgeBio Announces Publication Of New Analyses In Circulation: Heart Failure, Examining Kidney Func

- Acoramidis initiation was associated with rapid kidney-protective activity as exhibited in a hemod

BridgeBio Pharma Agrees To Sell Up To $1B Of Convertible Preferred Stock To Sixth Street And KKR's H

BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-st

Reported Sunday, BridgeBio PROPEL 3 Phase 3 Trial Published In NEJM, Oral Infigratinib Demonstrates

- Phase 3 PROPEL 3 data published today in NEJM were simultaneously presented at ICCBH in a late-bre

BridgeBio Pharma To Share Additional Data From PROPEL 3, Its Phase 3 Pivotal Study Of Oral Infigrati

BridgeBio will also share an oral presentation and four posters at the meeting highlighting quality